Centaurus Financial Inc. Takes Position in Solventum Co. (NYSE:SOLV)

Centaurus Financial Inc. bought a new position in shares of Solventum Co. (NYSE:SOLV) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 4,599 shares of the company’s stock, valued at approximately $321,000.

Several other large investors have also recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD acquired a new stake in shares of Solventum in the 1st quarter valued at approximately $5,889,000. CWM LLC acquired a new position in shares of Solventum during the 2nd quarter worth about $473,000. Great Valley Advisor Group Inc. acquired a new position in shares of Solventum during the 2nd quarter worth about $493,000. First Horizon Advisors Inc. bought a new stake in shares of Solventum in the 2nd quarter valued at about $58,000. Finally, Swedbank AB acquired a new stake in Solventum in the 2nd quarter valued at about $4,711,000.

Solventum Trading Down 0.2 %

Shares of Solventum stock opened at $71.50 on Wednesday. The company has a 50-day simple moving average of $70.51 and a two-hundred day simple moving average of $62.40. Solventum Co. has a twelve month low of $47.16 and a twelve month high of $96.05. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Stifel Nicolaus started coverage on Solventum in a research note on Tuesday, October 8th. They issued a “buy” rating and a $82.00 price objective on the stock. Wells Fargo & Company dropped their price target on Solventum from $69.00 to $64.00 and set an “equal weight” rating on the stock in a research note on Friday, August 9th. Piper Sandler lifted their price objective on shares of Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research report on Friday, November 8th. Morgan Stanley increased their price objective on shares of Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. Finally, The Goldman Sachs Group lifted their target price on shares of Solventum from $48.00 to $54.00 and gave the stock a “sell” rating in a report on Monday, August 12th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $68.00.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.